Capitalizing on resurgence: U.S. life science IPOs poised to spark leasing demand in 2024 and 2025

graph of number of completed and announced life science IPOs compared to leasing activity in the U.S. from 2015 to 2024
  • The number of initial public offerings (IPOs) in 2024 from life science companies with at least one location in the U.S. is on pace to match or exceed the number of IPOs in 2022 and 2023. Capital investment and post-valuation medians for IPOs in 2024 are at their highest levels since 2021, currently sitting at $110 million and $409 million, respectively.
  • Historically, the number of life science IPOs and associated total capital investment have correlated with the demand for leasing life science spaces, including lab/R&D and biomanufacturing operations, across the U.S.
  • With the prospect of the Federal Reserve lowering interest rates in the near-term and the presidential election coming to a close, a rise in public market activity for investors and life science companies could materialize further in 2024 and into 2025 with less uncertainty in the marketplace, sparking an uptick in leasing.

May 29, 2024

Additional resources

Get market intel